香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 截至2025年12月31日止年度（「2025財年」）的差額 根據目標公司2025財年之經審核財務報表，目標公司於2025財年之審核利潤約為4,772,000 港元。因此，賣方及張醫生已同意並將會於2026年4月30日或之前（即Rank Best根據買賣協 議向賣方及張醫生發出差額付款通知書之日起計一（1）個月內）向Rank Best支付相等於2025 財年之差額的75%，金額約為1,971,000港元。 茲提述盈健醫療集團有限公司（「本公司」）於 2025 年 1 月 3 日、2025 年 2 月 25 日及 2025 年 2 月 28 日（其中包括）收購祐德牙醫診所有限公司已發行股本的 75%（「該等公 告」）。除另有界定外，本公告所用詞彙與該等公告界定者具有相同涵義。 利潤保證 如該等公告所披露，賣方和張醫生各自向Rank Best保證，於截至2025年、2026年、2027年、 2028年及202 ...

Human Health Holdings Limited 盈健醫療集團有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code: 1419) （股份代號：1419） Dear Non-registered Shareholders(1), Notification of publication of 2026 Interim Report (the "Current Corporate Communication") on the Company's website The Current Corporate Communication of Human Health Holdings Limited (the "Company"), in both English and Chinese versions are available in the Investor Relations section of the Company's website at www.humanhe ...

Human Health Holdings Limited 盈健醫療集團有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code: 1419) （股份代號：1419） Dear Registered Shareholders, 26 March 2026 Notification of publication of 2026 Interim Report (the "Current Corporate Communication") on the Company's website The Current Corporate Communication of Human Health Holdings Limited (the "Company"), in both English and Chinese versions are available in the Investor Relations section of the Company's website at www. ...

Revenue and Profitability - The company's revenue for the interim period of fiscal year 2026 was approximately HKD 342.4 million, an increase of about HKD 26.6 million or 8.4% compared to the same period in fiscal year 2025[9]. - Revenue from primary care services increased by approximately HKD 7.3 million or 3.5% to about HKD 213.9 million, driven by an increase in patient visits[10]. - Revenue from dental services surged by approximately HKD 18.9 million or 67.5% to about HKD 46.8 million, primarily due to increased patient visits and the acquisition of Youde Dental Clinic[10]. - The group's profit for the interim period of FY2026 increased by approximately HKD 2.1 million or 12.3% to about HKD 18.9 million compared to FY2025[22]. - The net profit attributable to the company's owners for the interim period of FY2026 was approximately HKD 18.3 million, an increase of about HKD 1.5 million or 8.5% from FY2025[23]. - The group maintained a net profit margin of approximately 5.5% in FY2026 interim period[22]. - The group reported a net profit of HKD 18,898,000 for the period, compared to HKD 16,822,000 in the previous year, representing an increase of 12.3%[115]. Costs and Expenses - The cost of services provided rose by approximately HKD 15.8 million or 9.5% to about HKD 182.9 million, mainly due to increases in doctor and dentist fees and medical supplies costs[11]. - Administrative expenses rose by approximately HKD 6.3 million or 4.9% to about HKD 135.2 million, primarily due to increased employee-related expenses[18]. - Total costs of services provided amounted to HKD 182,881,000, an increase from HKD 167,070,000, primarily driven by higher costs for medical supplies and doctor fees[119]. Operational Developments - The group is actively participating in public health programs, enhancing community health services through collaborations with the Hong Kong government[27]. - The group is focusing on expanding telemedicine services and preventive health initiatives, including weight management programs and metabolic health screenings[26]. - The group is enhancing its integrated healthcare platform, H2, by expanding preventive medical services and personalized treatment plans[31]. - The group aims to strengthen its operational coordination and digital integration in the dental segment to establish long-term synergies[29]. - The group enhanced its diagnostic services by strengthening health education and customer interaction, including daily health consultations and a series of educational seminars on lifestyle management and disease prevention[32]. - The H2 community pharmacy offers various services, including pharmacist consultations, customized medication, and health screening services, aiming to optimize patient choices and experiences[32]. Workforce and Employment - As of December 31, 2025, the group had 408 full-time employees and 272 part-time employees, an increase from 388 full-time and 377 part-time employees as of December 31, 2024[69]. - The company has a diverse and skilled healthcare team of 464 members, including general practitioners, specialists, and various healthcare professionals, ensuring comprehensive and patient-centered care[46]. Financial Position - The net current assets as of December 31, 2025, were approximately HKD 414.7 million, an increase from HKD 383.9 million as of June 30, 2025[56]. - The company’s interest-bearing bank borrowings were approximately HKD 16.1 million as of December 31, 2025, with a capital debt ratio of about 2.0%[57]. - The company has approximately HKD 100.0 million in undrawn loan facilities as of December 31, 2025, maintaining financial flexibility[57]. - The company’s total assets as of December 31, 2025, were HKD 1,468,963,000, a decrease from HKD 1,471,571,000 as of June 30, 2025[98]. - The company’s cash and cash equivalents increased to HKD 474,531,000 from HKD 439,903,000, showing a growth of 7.8%[97]. Investments and Acquisitions - The company will continue to optimize synergies following the acquisition of Youde Dental, focusing on expanding high-end dental restoration and cosmetic services[50]. - The investment in the limited partnership is recorded at fair value, with a fair value of approximately HKD 61.0 million as of December 31, 2025, representing about 5.8% of the total assets of the group[64]. - The group recorded a fair value loss of approximately HKD 2.2 million related to the investment in the limited partnership[64]. Shareholder Information - The company’s issued share capital remains at HKD 3,796,000, with 379,552,233 shares issued as of both December 31, 2025, and June 30, 2025[141]. - As of December 31, 2025, the company’s major shareholders, including Mr. Chan and Dr. Pang, hold approximately 66.49% of the issued shares through a controlled corporation[84]. Stock Options and Incentives - The company has adopted a stock option plan, with 3,200,000 options granted and 150,000 options unexercised as of December 31, 2025[77]. - The exercise price for the stock options is set at HKD 2.09, with the options exercisable from June 1, 2021, to May 31, 2027[82]. - The total number of stock options and share rewards authorized for grant under the plans is capped at 37,955,223 shares, representing approximately 10% of the issued shares as of the adoption date[81]. Market Outlook - The company maintains a cautiously optimistic outlook for the Hong Kong private healthcare sector, driven by strong demand from an aging population and increasing health awareness[49].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 盈健醫療集團有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01419 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/ ...

Core Viewpoint - Yingjian Medical (01419) reported a mid-term performance for the six months ending December 31, 2025, showing a revenue of approximately HKD 342 million, representing an increase of about HKD 26.6 million or 8.4% compared to the mid-term of the 2025 fiscal year [1] Financial Performance - The profit attributable to the company's owners was approximately HKD 18.3 million, an increase of about HKD 1.5 million or 8.5% from approximately HKD 16.8 million in the mid-term of the 2025 fiscal year [1] - Basic earnings per share were approximately HKD 0.048 [1] Revenue Growth Drivers - The revenue growth from the group's general medical services was primarily due to an increase in patient visits, which was offset by a decrease in average spending per visit [1]

Core Viewpoint - Yingjian Medical (01419) reported a mid-term performance for the six months ending December 31, 2025, showing a revenue of approximately HKD 342 million, an increase of about HKD 26.6 million or 8.4% compared to the mid-term of the 2025 fiscal year [1] Group 1: Financial Performance - The company's profit attributable to shareholders was approximately HKD 18.3 million, an increase of about HKD 1.5 million or 8.5% compared to the mid-term of the 2025 fiscal year [1] - Basic earnings per share were approximately HKD 0.048 [1] Group 2: Revenue Drivers - The revenue growth from the group's general medical services was primarily due to an increase in patient visits, offset by a decrease in average spending per visit [1]

Core Viewpoint - 盈健医疗 (01419.HK) reported a mid-term performance for the six months ending December 31, 2025, showing a revenue increase of approximately 8.4% compared to the same period in 2025 [1] Financial Performance - The group's revenue for the mid-term of the 2026 fiscal year was approximately 342.4 million HKD, an increase of about 26.6 million HKD from the mid-term of the 2025 fiscal year [1] - The profit attributable to the company's owners for the mid-term of the 2026 fiscal year was approximately 18.3 million HKD, up by about 1.5 million HKD or 8.5% from the mid-term of the 2025 fiscal year [1] - The basic earnings per share for the mid-term of the 2026 fiscal year were approximately 4.8 HKD cents, compared to approximately 4.4 HKD cents for the mid-term of the 2025 fiscal year [1]

Financial Performance - The group's revenue for the six months ended December 31, 2025, was approximately HKD 342.4 million, an increase of about HKD 26.6 million or 8.4% compared to the same period in 2024[4] - The profit attributable to the company's owners for the six months ended December 31, 2025, was approximately HKD 18.3 million, an increase of about HKD 1.5 million or 8.5% compared to HKD 16.8 million in the same period of 2024[4] - Basic earnings per share for the six months ended December 31, 2025, were approximately HKD 0.048, compared to HKD 0.044 for the same period in 2024[4] - The gross profit for the six months ended December 31, 2025, was HKD 159.5 million, up from HKD 148.7 million in the same period of 2024[5] - The total comprehensive income for the six months ended December 31, 2025, was HKD 15.3 million, compared to HKD 16.3 million for the same period in 2024[6] - The net profit for the six months ended December 31, 2025, was HKD 18.9 million, compared to HKD 16.8 million for the same period in 2024[5] - Adjusted profit before tax for the six months ended December 31, 2025, was HKD 22,654,000, compared to HKD 20,066,000 for the same period in 2024, reflecting an increase of approximately 13.0%[22] Revenue Breakdown - The revenue breakdown shows that General Medical Services generated HKD 213,916,000, Specialist Medical Services generated HKD 81,663,000, and Dental Services generated HKD 46,772,000 for the six months ended December 31, 2025[17] - The revenue breakdown by service type for the six months ended December 31, 2025, includes: General medical services at HKD 213.9 million (up 3.5%), Specialist medical services at HKD 81.7 million (up 0.5%), and Dental services at HKD 46.8 million (up 67.5%) compared to the previous year[35] - The group's revenue from primary healthcare services increased by approximately HKD 7.3 million or 3.5% to about HKD 213.9 million for the interim period of FY2026[36] - Revenue from specialist medical services slightly increased by approximately HKD 0.4 million or 0.5% to about HKD 81.7 million for the interim period of FY2026[36] - Revenue from dental services surged by approximately HKD 18.9 million or 67.5% to about HKD 46.8 million for the interim period of FY2026, primarily due to an increase in patient visits and the acquisition of Youde Dental Clinic[36] Expenses and Costs - The group's administrative and other expenses for the six months ended December 31, 2025, were HKD 135.2 million, an increase from HKD 128.9 million in the same period of 2024[5] - The total cost of services provided for the six months ended December 31, 2025, was HKD 167,070,000, down from HKD 182,881,000 in 2024, indicating a reduction of about 8.7%[22] - The Group's total expenses for the six months ended December 31, 2025, included HKD 110,508,000 in doctor and dentist fees, compared to HKD 118,021,000 in 2024, a decrease of approximately 6.4%[22] - The group incurred other employee benefits expenses of HKD 3,157,000 for the six months ended December 31, 2025, compared to HKD 3,360,000 for the same period in 2024[28] Taxation and Financing - The income tax expense for the six months ended December 31, 2025, was HKD 3.8 million, compared to HKD 3.2 million in the same period of 2024[5] - The total tax expense for the six months ended December 31, 2025, was HKD 3,244,000, a decrease from HKD 3,756,000 for the same period in 2024[28] - Financing costs for the six months ended December 31, 2025, totaled HKD 3,290,000, slightly up from HKD 3,230,000 in 2024[23] Assets and Liabilities - Non-current assets totaled HKD 444,547,000 as of December 31, 2025, compared to HKD 484,322,000 as of June 30, 2025, reflecting a decrease of approximately 8.2%[7] - Current assets amounted to HKD 608,706,000 as of December 31, 2025, an increase from HKD 587,649,000 as of June 30, 2025, representing a growth of about 3.5%[7] - Total liabilities decreased from HKD 193,996,000 as of June 30, 2025, to HKD 193,996,000 as of December 31, 2025, indicating a stable liability position[8] - The net assets of the company increased to HKD 786,259,000 as of December 31, 2025, compared to HKD 781,749,000 as of June 30, 2025, showing a growth of approximately 0.7%[8] - Cash and cash equivalents rose to HKD 474,531,000 as of December 31, 2025, up from HKD 439,903,000 as of June 30, 2025, marking an increase of about 7.8%[7] - The company reported a total equity of HKD 786,259,000 as of December 31, 2025, compared to HKD 781,749,000 as of June 30, 2025, reflecting a slight increase of 0.6%[8] Employee and Governance - As of December 31, 2025, the group has 408 full-time employees, an increase from 388 the previous year, and 272 part-time employees, a decrease from 377[102] - The company has implemented a hiring policy based on market conditions and business needs, focusing on professional healthcare staff[103] - The group has adopted the corporate governance code as per the Hong Kong Stock Exchange's listing rules and has complied with all applicable provisions[105] Community and Public Health Initiatives - The group continues to collaborate closely with the Hong Kong government on public health initiatives, including seasonal flu vaccination and chronic disease management programs[53] - The group maintains a strong commitment to community health by providing vaccination services at elderly centers and schools, integrating digital health solutions[52] - The group is actively participating in various public health plans, which are crucial for delivering preventive care and chronic disease management services to the community[53] Digital Transformation and Service Expansion - The group is committed to advancing its digital transformation roadmap to improve operational efficiency and patient engagement, particularly through the expansion of telemedicine services[85] - The group is focusing on operational coordination and digital integration in its dental services to establish a foundation for long-term synergies following the acquisition of Youde Dental[57] - The group is expanding telemedicine services, now offering consultations on Sundays to enhance service accessibility and scalability[52] Future Outlook - The group anticipates strong demand for healthcare driven by an aging population, increased health awareness, and a growing emphasis on preventive medicine[81] - The group plans to expand its primary care network by identifying high-potential residential and commercial areas to enhance accessibility to basic healthcare services[82] - The focus for the upcoming period will be on advancing screening and diagnostic services, particularly for chronic diseases and age-related conditions[83] - The group aims to enhance its specialist medical capabilities and expand its service offerings following the acquisition of a dental practice[84]

Group 1 - The company, Yingjian Medical (01419.HK), announced that its board meeting will be held on February 26, 2026, in Hong Kong to approve the interim results for the six months ending December 31, 2025 [1] - The meeting will also consider the proposal for the distribution of an interim dividend, if any [1]